



Clinical trial results:

A Phase 3, observer-blind, randomized, placebo-controlled study to evaluate the non-inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50-59 years of age, including adults at increased risk of respiratory syncytial virus lower respiratory tract disease, compared to older adults ≥ 60 years of age

Summary

EudraCT number	2022-001981-36
Trial protocol	DE ES NL PL
Global end of trial date	12 February 2024

Results information

Result version number	v1
This version publication date	26 June 2024
First version publication date	26 June 2024

Trial information

Trial identification

Sponsor protocol code	219238
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	GSK Response Center, GlaxoSmithKline, 44 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 44 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	13 March 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 March 2023
Global end of trial reached?	Yes
Global end of trial date	12 February 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

- To demonstrate the non-inferiority (NI) of the humoral immune response in healthy participants 50-59 years of age (YOA) compared to OA (≥ 60 YOA) for the RSV-A strain after RSVPreF3 OA investigational vaccine administration.
- To demonstrate the NI of the humoral immune response in healthy participants 50-59 YOA compared to OA for the RSV-B strain after RSVPreF3 OA investigational vaccine administration.
- To demonstrate the NI of the humoral immune response in participants 50-59 YOA at increased risk of RSV-LRTD compared to OA for the RSV-A strain after RSVPreF3 OA investigational vaccine administration.
- To demonstrate the NI of the humoral immune response in participants 50-59 YOA at increased risk of RSV-LRTD compared to OA for the RSV-B strain after RSVPreF3 OA investigational vaccine administration.

Protection of trial subjects:

Study participants were observed closely for at least 30 minutes after the administration of the study interventions. Appropriate medical treatment was readily available during the observation period in case of anaphylaxis or syncope.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 October 2022
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 179
Country: Number of subjects enrolled	Canada: 223
Country: Number of subjects enrolled	Germany: 248
Country: Number of subjects enrolled	Japan: 152
Country: Number of subjects enrolled	Netherlands: 39
Country: Number of subjects enrolled	Poland: 144
Country: Number of subjects enrolled	Spain: 199
Country: Number of subjects enrolled	United States: 360
Worldwide total number of subjects	1544
EEA total number of subjects	630

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1273
From 65 to 84 years	264
85 years and over	7

Subject disposition

Recruitment

Recruitment details:

Out of 1544 participants enrolled in this study, only 1534 received at least one study intervention, from which 1 participant in OA-RSV group received placebo instead of RSVPreF3 OA vaccine and was excluded from the group. The Exposed set included only 1533 participants.

Pre-assignment

Screening details:

The results for this study were reported until Day 31 for immunogenicity analysis and up to Month 6 for safety analyses, since this is a primary completion posting. Data for final analysis will be updated at the time of End of Study (Final posting).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Adults HA-RSV Group

Arm description:

Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

Arm type	Experimental
Investigational medicinal product name	RSVPreF3 OA vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

One 0.5mL dose administered at Day 1 in the deltoid of the non-dominant arm.

Arm title	Adults HA-Placebo Group
------------------	-------------------------

Arm description:

Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

Arm type	Placebo
Investigational medicinal product name	Sodium chloride (NaCl)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

One dose of approximately 0.7 mL of NaCl solution administered at Day 1 in the deltoid of the non-dominant arm.

Arm title	Adults AIR-RSV Group
------------------	----------------------

Arm description:

Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

Arm type	Experimental
Investigational medicinal product name	RSVPreF3 OA vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

One 0.5mL dose administered at Day 1 in the deltoid of the non-dominant arm.

Arm title	Adults AIR-Placebo Group
------------------	--------------------------

Arm description:

Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

Arm type	Placebo
Investigational medicinal product name	Sodium chloride (NaCl)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

One dose of approximately 0.7 mL of NaCl solution administered at Day 1 in the deltoid of the non-dominant arm.

Arm title	OA-RSV Group
------------------	--------------

Arm description:

Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

Arm type	Experimental
Investigational medicinal product name	RSVPreF3 OA vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

One 0.5mL dose administered at Day 1 in the deltoid of the non-dominant arm.

Number of subjects in period 1^[1]	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group
Started	383	192	386
Completed	380	191	384
Not completed	3	1	2
Lost to follow-up	3	-	2
Consent withdrawal, not due to a (S)AE	-	1	-

Number of subjects in period 1^[1]	Adults AIR-Placebo Group	OA-RSV Group
Started	191	381
Completed	190	381
Not completed	1	0

Lost to follow-up	-	-
Consent withdrawal, not due to a (S)AE	1	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The baseline period is reporting the number of participants included in the Exposed set, the worldwide number of participants is reporting the number of participants included in the Enrolled set.

Baseline characteristics

Reporting groups

Reporting group title	Adults HA-RSV Group
Reporting group description: Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.	
Reporting group title	Adults HA-Placebo Group
Reporting group description: Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.	
Reporting group title	Adults AIR-RSV Group
Reporting group description: Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.	
Reporting group title	Adults AIR-Placebo Group
Reporting group description: Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.	
Reporting group title	OA-RSV Group
Reporting group description: Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.	

Reporting group values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group
Number of subjects	383	192	386
Age categorical Units: Subjects			
Adults (50-59 years)	383	192	386
Adults (60-69 years)	0	0	0
Adults (70-79 years)	0	0	0
80 years and above	0	0	0
Age continuous Units: years			
median	54.8	54.7	55.3
standard deviation	± 2.8	± 2.8	± 2.8
Sex: Female, Male Units: Participants			
MALE	162	73	200
FEMALE	221	119	186
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	1	0	4
Asian	41	22	42
Black or African American	14	8	15
Native Hawaiian or other Pacific Islander	0	0	0
White	320	158	324
Multiple	4	3	1

Unknown	3	1	0
---------	---	---	---

Age, Continuous Units: YEARS arithmetic mean standard deviation	54.8 ± 2.8	54.7 ± 2.8	55.3 ± 2.8
--	---------------	---------------	---------------

Reporting group values	Adults AIR-Placebo Group	OA-RSV Group	Total
Number of subjects	191	381	1533
Age categorical Units: Subjects			
Adults (50-59 years)	191	0	1152
Adults (60-69 years)	0	202	202
Adults (70-79 years)	0	130	130
80 years and above	0	49	49
Age continuous Units: years median standard deviation	55.6 ± 2.8	69.5 ± 6.9	-
Sex: Female, Male Units: Participants			
MALE	106	193	734
FEMALE	85	188	799
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	3	1	9
Asian	23	43	171
Black or African American	3	11	51
Native Hawaiian or other Pacific Islander	2	1	3
White	158	324	1284
Multiple	1	0	9
Unknown	1	1	6
Age, Continuous Units: YEARS arithmetic mean standard deviation	55.6 ± 2.8	69.5 ± 6.9	-

End points

End points reporting groups

Reporting group title	Adults HA-RSV Group
Reporting group description: Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.	
Reporting group title	Adults HA-Placebo Group
Reporting group description: Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.	
Reporting group title	Adults AIR-RSV Group
Reporting group description: Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.	
Reporting group title	Adults AIR-Placebo Group
Reporting group description: Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.	
Reporting group title	OA-RSV Group
Reporting group description: Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.	

Primary: RSV-A neutralization titers expressed as group geometric mean titer (GMT) in healthy participants compared to OA-RSV Group

End point title	RSV-A neutralization titers expressed as group geometric mean titer (GMT) in healthy participants compared to OA-RSV Group ^[1]
End point description: Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay. The corresponding antibody titers were expressed in Estimated Dilution 60 (ED60) and were measured on blood samples collected from vaccinated maternal subjects. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA_RSV and OA_RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan. Analysis was performed on the per protocol set (PPS) for humoral analysis which included all eligible participants who received the study intervention as per protocol, had RSV-A immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.	
End point type	Primary
End point timeframe: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults HA-RSV Group compared to OA-RSV Group.

End point values	Adults HA-RSV Group	OA-RSV Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	326	342		
Units: Titer				
geometric mean (confidence interval 95%)	7893.5 (7167.5 to 8692.9)	7492.6 (6819.1 to 8232.7)		

Statistical analyses

Statistical analysis title	RSV-A ratio in OA-RSV over Adults-HA-RSV groups
Statistical analysis description:	
To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to healthy adults aged 50-59 years of age compared with older adults aged 60 years of age or above.	
Comparison groups	Adults HA-RSV Group v OA-RSV Group
Number of subjects included in analysis	668
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	GMT Ratio
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.09

Primary: RSV-A neutralization titers expressed as group seroresponse rate (SRR) difference in healthy participants compared to OA-RSV group

End point title	RSV-A neutralization titers expressed as group seroresponse rate (SRR) difference in healthy participants compared to OA-RSV group ^[2]
-----------------	---

End point description:

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to 4 (≥ 4).

Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had SRR results for RSV-A at pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

End point type	Primary
----------------	---------

End point timeframe:

At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The purpose of this endpoint was to present analysis only for Adults HA-RSV Group compared to OA-RSV Group.

End point values	Adults HA-RSV Group	OA-RSV Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	270	275		
Units: Percentage of participants				
number (confidence interval 95%)	82.8 (78.3 to 86.8)	80.4 (75.8 to 84.5)		

Statistical analyses

Statistical analysis title	SRR ratio in OA-RSV minus Adults-HA-RSV groups
Statistical analysis description:	
To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to healthy adults aged 50-59 years of age compared with older adults aged 60 years of age or above.	
Comparison groups	Adults HA-RSV Group v OA-RSV Group
Number of subjects included in analysis	545
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-2.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.3
upper limit	3.5

Primary: RSV-B neutralization titers expressed as group GMT in healthy participants compared to OA-RSV Group

End point title	RSV-B neutralization titers expressed as group GMT in healthy participants compared to OA-RSV Group ^[3]
-----------------	--

End point description:

Serological assays for the determination of antibodies against RSV-B were performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA_RSV and OA_RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan. Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had RSV-B immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

End point type	Primary
----------------	---------

End point timeframe:

At 1 month after the RSVPreF3 OA vaccine administration (Day 31)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults HA-RSV Group compared to OA-RSV Group.

End point values	Adults HA-RSV Group	OA-RSV Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	326	341		
Units: Titer				
geometric mean (confidence interval 95%)	9009.5 (8226.6 to 9866.6)	8058.2 (7373.1 to 8807.0)		

Statistical analyses

Statistical analysis title	RSV-B ratio in OA-RSV over Adults-HA-RSV groups
Statistical analysis description:	
To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to healthy adults aged 50-59 years of age compared with older adults aged 60 years of age or above.	
Comparison groups	Adults HA-RSV Group v OA-RSV Group
Number of subjects included in analysis	667
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	GMT Ratio
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.02

Primary: RSV-B neutralization titers expressed as group SRR in healthy participants compared to OA-RSV Group

End point title	RSV-B neutralization titers expressed as group SRR in healthy participants compared to OA-RSV Group ^[4]
End point description:	
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) ≥ 4 . Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had SRR results for RSV-B at pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.	
End point type	Primary

End point timeframe:

At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults HA-RSV Group compared to OA-RSV Group.

End point values	Adults HA-RSV Group	OA-RSV Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	255	254		
Units: Percentage of participants				
number (confidence interval 95%)	78.2 (73.3 to 82.6)	74.5 (69.5 to 79.0)		

Statistical analyses

Statistical analysis title	SRR ratio in OA-RSV minus Adults-HA-RSV groups
Statistical analysis description:	
To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to healthy adults aged 50-59 years of age compared with older adults aged 60 years of age or above.	
Comparison groups	Adults HA-RSV Group v OA-RSV Group
Number of subjects included in analysis	509
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-3.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.17
upper limit	2.74

Primary: RSV-A neutralization titers expressed as group GMT titer in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group

End point title	RSV-A neutralization titers expressed as group GMT titer in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group ^[5]
-----------------	---

End point description:

Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR_RSV and OA_RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan. Analysis was performed on the per protocol set (PPS) for humoral analysis which included all eligible participants who received the study intervention as per protocol, had RSV-A immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

End point type	Primary
----------------	---------

End point timeframe:

At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults-AIR-RSV Group compared to OA-RSV Group.

End point values	Adults AIR-RSV Group	OA-RSV Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	343	342		
Units: Titer				
geometric mean (confidence interval 95%)	8922.7 (8118.2 to 9806.9)	7440.1 (6768.4 to 8178.5)		

Statistical analyses

Statistical analysis title	RSV-A ratio in OA-RSV over Adults-AIR-RSV groups
-----------------------------------	--

Statistical analysis description:

To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to adults at increased risk of RSV-LRTD aged 50-59 years of age compared with older adults aged 60 years of age or above.

Comparison groups	Adults AIR-RSV Group v OA-RSV Group
Number of subjects included in analysis	685
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	GMT Ratio
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	0.95

Primary: RSV-B neutralization titers expressed as group GMT in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group

End point title	RSV-B neutralization titers expressed as group GMT in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group ^[6]
-----------------	---

End point description:

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR_RSV and OA_RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan. Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had RSV-B immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

End point type	Primary
----------------	---------

End point timeframe:

At 1 month after the RSVPreF3 OA vaccine administration (Day 31)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults-AIR-RSV Group compared to OA-RSV Group.

End point values	Adults AIR-RSV Group	OA-RSV Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	343	341		
Units: Titer				
geometric mean (confidence interval 95%)	10054.7 (9225.4 to 10958.7)	8062.8 (7395.9 to 8789.9)		

Statistical analyses

Statistical analysis title	RSV-B ratio in OA-RSV over Adults AIR-RSV groups
Statistical analysis description:	
To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to adults at increased risk of RSV-LRTD aged 50-59 years of age compared with older adults aged 60 years of age or above.	
Comparison groups	Adults AIR-RSV Group v OA-RSV Group
Number of subjects included in analysis	684
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	GMT Ratio
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	0.91

Primary: RSV-A neutralization titers expressed as group SRR in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group

End point title	RSV-A neutralization titers expressed as group SRR in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group ^[7]
End point description:	
<p>The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) ≥ 4. Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had SRR results for RSV-A at pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.</p>	
End point type	Primary
End point timeframe:	
At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)	
Notes:	
<p>[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults-AIR-RSV Group compared to OA-RSV Group.</p>	

End point values	Adults AIR-RSV Group	OA-RSV Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	298	275		
Units: Percentage of participants				
number (confidence interval 95%)	86.9 (82.8 to 90.3)	80.4 (75.8 to 84.5)		

Statistical analyses

Statistical analysis title	SRR ratio in OA-RSV minus Adults-AIR-RSV groups
----------------------------	---

Statistical analysis description:

To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to adults at increased risk of RSV-LRTD aged 50-59 years of age compared with older adults aged 60 years of age or above.

Comparison groups	Adults AIR-RSV Group v OA-RSV Group
Number of subjects included in analysis	573
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-6.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.05
upper limit	-0.94

Primary: RSV-B neutralization titers expressed as group SRR in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group

End point title	RSV-B neutralization titers expressed as group SRR in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group ^[8]
-----------------	---

End point description:

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) ≥ 4 . Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had SRR results for RSV-B at pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

End point type	Primary
----------------	---------

End point timeframe:

At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The purpose of this endpoint was to present analysis only for Adults-AIR-RSV Group compared to OA-RSV Group.

End point values	Adults AIR-RSV Group	OA-RSV Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	280	254		
Units: Percentage of participants				
number (confidence interval 95%)	81.6 (77.1 to 85.6)	74.5 (69.5 to 79.0)		

Statistical analyses

Statistical analysis title	SRR ratio in OA-RSV minus Adults AIR-RSV groups
-----------------------------------	---

Statistical analysis description:

To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to adults at increased risk of RSV-LRTD aged 50-59 years of age compared with older adults aged 60 years of age or above.

Comparison groups	Adults AIR-RSV Group v OA-RSV Group
Number of subjects included in analysis	534
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in percentage
Point estimate	-7.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.34
upper limit	-0.94

Secondary: Percentage of participants reporting each solicited administration site event (pain, redness and swelling)

End point title	Percentage of participants reporting each solicited administration site event (pain, redness and swelling)
-----------------	--

End point description:

Assessed solicited administration site events were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema and swelling symptom = symptom reported with a surface diameter greater than 0 millimeters.

Analysis was based on the Exposed Set (ES), which included all participants who received the study intervention and had data for solicited administration site events analysis at the assessed timeframe.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	377	191	379	188
Units: Percentage of participants				
number (confidence interval 95%)				
Erythema	11.9 (8.8 to 15.6)	0.5 (0.0 to 2.9)	14.5 (11.1 to 18.5)	0.5 (0.0 to 2.9)
Pain	76.4 (71.8 to 80.6)	10.5 (6.5 to 15.7)	75.2 (70.5 to 79.5)	13.8 (9.2 to 19.6)
Swelling	9.3 (6.6 to 12.7)	1.0 (0.1 to 3.7)	11.6 (8.6 to 15.3)	0.5 (0.0 to 2.9)

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	379			
Units: Percentage of participants				
number (confidence interval 95%)				
Erythema	12.1 (9.0 to 15.9)			
Pain	61.2 (56.1 to 66.1)			
Swelling	7.7 (5.2 to 10.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants reporting each solicited systemic event (fever, headache, muscle pain, joint pain, tiredness)

End point title	Percentage of participants reporting each solicited systemic event (fever, headache, muscle pain, joint pain, tiredness)
-----------------	--

End point description:

Assessed solicited systemic events were arthralgia, fatigue, headache, myalgia and fever [temperature equal to or above (\geq) 38 degrees Celsius ($^{\circ}\text{C}$)]. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.

Analysis was based on the Exposed Set (ES), which included all participants who received the study intervention and had data for solicited systemic events analysis at the assessed timeframe.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	377	191	379	189
Units: Percentage of participants				
number (confidence interval 95%)				
Arthralgia	26.0 (21.6 to 30.7)	5.8 (2.9 to 10.1)	20.8 (16.9 to 25.3)	10.1 (6.2 to 15.3)
Fatigue	43.8 (38.7 to 48.9)	17.3 (12.2 to 23.4)	35.9 (31.0 to 40.9)	19.0 (13.7 to 25.4)
Headache	35.8 (31.0 to 40.9)	16.8 (11.8 to 22.8)	27.7 (23.3 to 32.5)	16.9 (11.9 to 23.1)
Myalgia	39.0 (34.0 to 44.1)	5.8 (2.9 to 10.1)	32.2 (27.5 to 37.2)	13.8 (9.2 to 19.5)
Fever	3.7 (2.0 to 6.2)	1.0 (0.1 to 3.7)	2.6 (1.3 to 4.8)	1.1 (0.1 to 3.8)

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	379			
Units: Percentage of participants				
number (confidence interval 95%)				
Arthralgia	12.9 (9.7 to 16.7)			
Fatigue	23.7 (19.6 to 28.4)			
Headache	21.1 (17.1 to 25.6)			
Myalgia	21.1 (17.1 to 25.6)			
Fever	1.6 (0.6 to 3.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants reporting any unsolicited adverse events (AEs)

End point title	Percentage of participants reporting any unsolicited adverse events (AEs)
End point description:	
<p>Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.</p> <p>Analysis was based on the Exposed Set (ES), which included all participants who received the study intervention and had data for assessed timeframe and unsolicited events analysis.</p>	
End point type	Secondary
End point timeframe:	
During the 30-day follow up period after vaccination (vaccine or placebo administered on Day 1)	

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	383	192	386	191
Units: Percentage of participants				
number (confidence interval 95%)	13.1 (9.8 to 16.8)	13.5 (9.0 to 19.2)	14.8 (11.4 to 18.7)	9.9 (6.1 to 15.1)

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	381			
Units: Percentage of participants				
number (confidence interval 95%)	16.3 (12.7 to 20.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants reporting any serious adverse events (SAEs)

End point title	Percentage of participants reporting any serious adverse events (SAEs)
-----------------	--

End point description:

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

Analysis was based on the ES, which included all participants who received the study intervention. Analysis per group is based on the administered intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

From the day of the vaccination (Day 1) up to 6 months post dose (Month 6)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	383	192	386	191
Units: Percentage of participants				
number (confidence interval 95%)	0.5 (0.1 to 1.9)	2.1 (0.6 to 5.2)	3.6 (2.0 to 6.0)	2.1 (0.6 to 5.3)

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	381			
Units: Percentage of participants				
number (confidence interval 95%)	2.4 (1.1 to 4.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants reporting any potential immune mediated diseases (pIMDs)

End point title	Percentage of participants reporting any potential immune mediated diseases (pIMDs)
-----------------	---

End point description:

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Analysis was based on the ES, which included all participants who received the study intervention.

Analysis per group is based on the administered intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

From the day of the vaccination (Day 1) up to 6 months post dose (Month 6)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	383	192	386	191
Units: Percentage of participants				
number (confidence interval 95%)	0 (0 to 0)	0 (0 to 0)	1.0 (0.3 to 2.6)	0.5 (0.0 to 2.9)

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	381			
Units: Percentage of participants				
number (confidence interval 95%)	0.8 (0.2 to 2.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants reporting SAEs related to study intervention administration

End point title	Percentage of participants reporting SAEs related to study intervention administration
End point description: An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.	
End point type	Secondary
End point timeframe: From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)	

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[9]	0 ^[10]	0 ^[11]	0 ^[12]
Units: Percentage of participants				
number (confidence interval 95%)	(to)	(to)	(to)	(to)

Notes:

[9] - Data for this analysis will be updated at the time of final posting.

[10] - Data for this analysis will be updated at the time of final posting.

[11] - Data for this analysis will be updated at the time of final posting.

[12] - Data for this analysis will be updated at the time of final posting.

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[13]			
Units: Percentage of participants				
number (confidence interval 95%)	(to)			

Notes:

[13] - Data for this analysis will be updated at the time of final posting.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants reporting pIMDs related to study intervention administration

End point title	Percentage of participants reporting pIMDs related to study intervention administration
End point description: pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Analysis was based on the ES, which included all participants who received the study intervention. Analysis per group is based on the administered intervention.	
End point type	Secondary
End point timeframe: From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)	

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[14]	0 ^[15]	0 ^[16]	0 ^[17]
Units: Percentage of participants				
number (confidence interval 95%)	(to)	(to)	(to)	(to)

Notes:

[14] - Data for this analysis will be updated at the time of final posting.

[15] - Data for this analysis will be updated at the time of final posting.

[16] - Data for this analysis will be updated at the time of final posting.

[17] - Data for this analysis will be updated at the time of final posting.

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[18]			
Units: Percentage of participants				
number (confidence interval 95%)	(to)			

Notes:

[18] - Data for this analysis will be updated at the time of final posting.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants reporting any fatal SAEs

End point title	Percentage of participants reporting any fatal SAEs
-----------------	---

End point description:

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

Analysis was based on the ES, which included all participants who received the study intervention.

Analysis per group is based on the administered intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[19]	0 ^[20]	0 ^[21]	0 ^[22]
Units: Percentage of participants				
number (confidence interval 95%)	(to)	(to)	(to)	(to)

Notes:

[19] - Data for this analysis will be updated at the time of final posting.

[20] - Data for this analysis will be updated at the time of final posting.

[21] - Data for this analysis will be updated at the time of final posting.

[22] - Data for this analysis will be updated at the time of final posting.

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[23]			
Units: Percentage of participants				
number (confidence interval 95%)	(to)			

Notes:

[23] - Data for this analysis will be updated at the time of final posting.

Statistical analyses

No statistical analyses for this end point

Secondary: RSV-A neutralization titers expressed as GMT, up to one month post-intervention

End point title	RSV-A neutralization titers expressed as GMT, up to one month post-intervention
-----------------	---

End point description:

Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA_RSV, Adults HA-Placebo, Adult AIR_RSV, Adult AIR_Placebo and OA_RSV groups.

Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for the assessed analysis, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	347	181	365	186
Units: Titer				
geometric mean (confidence interval 95%)				
Day 1	768.8 (704.7 to 838.9)	772.0 (677.9 to 879.1)	781.7 (727.5 to 840.0)	729.8 (648.6 to 821.0)
Day 31	7925.4 (7125.6 to 8815.0)	796.9 (696.4 to 912.0)	8821.9 (7971.0 to 9763.6)	774.9 (683.7 to 878.3)

End point values	OA-RSV Group			
------------------	--------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	362			
Units: Titer				
geometric mean (confidence interval 95%)				
Day 1	772.2 (706.6 to 843.8)			
Day 31	7461.9 (6724.9 to 8279.6)			

Statistical analyses

No statistical analyses for this end point

Secondary: RSV-B neutralization titers expressed as GMT, up to one month post-intervention

End point title	RSV-B neutralization titers expressed as GMT, up to one month post-intervention
-----------------	---

End point description:

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA_RSV, Adults HA-Placebo, Adult AIR_RSV, Adult AIR_Placebo and OA_RSV groups.

Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	347	181	365	186
Units: Titer				
geometric mean (confidence interval 95%)				
Day 1	1091.1 (1000.3 to 1190.2)	1197.7 (1055.7 to 1358.8)	1141.6 (1051.0 to 1240.0)	1167.2 (1035.0 to 1316.1)
Day 31	8971.9 (8109.6 to 9925.8)	1145.3 (1012.4 to 1295.5)	9967.3 (9059.3 to 10966.3)	1141.7 (1007.9 to 1293.1)

End point values	OA-RSV Group			
------------------	--------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	362			
Units: Titer				
geometric mean (confidence interval 95%)				
Day 1	1104.2 (1016.2 to 1199.9)			
Day 31	8144.5 (7388.9 to 8977.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: RSV-A neutralization titers expressed as GMT at Month 6 and Month 12 post-intervention

End point title	RSV-A neutralization titers expressed as GMT at Month 6 and Month 12 post-intervention
End point description:	
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.	
End point type	Secondary
End point timeframe:	
At 6 months and at 12 months after study intervention administration	

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[24]	0 ^[25]	0 ^[26]	0 ^[27]
Units: Titer				
geometric mean (confidence interval 95%)	(to)	(to)	(to)	(to)

Notes:

[24] - Data for this analysis will be updated at the time of final posting.

[25] - Data for this analysis will be updated at the time of final posting.

[26] - Data for this analysis will be updated at the time of final posting.

[27] - Data for this analysis will be updated at the time of final posting.

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[28]			
Units: Titer				
geometric mean (confidence interval 95%)	(to)			

Notes:

[28] - Data for this analysis will be updated at the time of final posting.

Statistical analyses

No statistical analyses for this end point

Secondary: RSV-B neutralization titers expressed as GMT, at Month 6 and Month 12 post-intervention

End point title	RSV-B neutralization titers expressed as GMT, at Month 6 and Month 12 post-intervention
-----------------	---

End point description:

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60.

Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for the assessed analysis, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 months and at 12 months after study intervention administration

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[29]	0 ^[30]	0 ^[31]	0 ^[32]
Units: Titer				
geometric mean (confidence interval 95%)	(to)	(to)	(to)	(to)

Notes:

[29] - Data for this analysis will be updated at the time of final posting.

[30] - Data for this analysis will be updated at the time of final posting.

[31] - Data for this analysis will be updated at the time of final posting.

[32] - Data for this analysis will be updated at the time of final posting.

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[33]			
Units: Titer				
geometric mean (confidence interval 95%)	(to)			

Notes:

[33] - Data for this analysis will be updated at the time of final posting.

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of RSVPreF3-specific cluster of differentiation (CD)4+ T cells expressing at least 2 activation markers, up to one month post-intervention

End point title	Frequency of RSVPreF3-specific cluster of differentiation (CD)4+ T cells expressing at least 2 activation markers, up to one month post-intervention
-----------------	--

End point description:

Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF- α) and interferon gamma (IFN- γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Analysis was performed on Cell-Mediated immune (CMI) sub-cohort of the PPS, which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for RSVPreF3 OA specific CD4+ T cells, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

At pre-study intervention administration (Day 1) and 1 months after study intervention administration (Day 31)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	28	55	27
Units: CD4+ T cells/million cells				
geometric mean (standard deviation)				
Day 1	102.7 (\pm 0.9)	125.6 (\pm 0.9)	161.5 (\pm 0.6)	114.7 (\pm 0.9)
Day 31	1282.5 (\pm 0.4)	167.7 (\pm 0.8)	1043.6 (\pm 0.6)	131.9 (\pm 0.8)

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	25			
Units: CD4+ T cells/million cells				
geometric mean (standard deviation)				
Day 1	108.8 (\pm 0.9)			
Day 31	1029.2 (\pm 0.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of RSVPreF3-specific CD4+ T cells expressing at least 2 activation markers, at Month 6 and Month 12 post-intervention

End point title	Frequency of RSVPreF3-specific CD4+ T cells expressing at least 2 activation markers, at Month 6 and Month 12 post-intervention
-----------------	---

End point description:

Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L),

41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Analysis was performed on Cell-Mediated immune (CMI) sub-cohort of the PPS, which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for RSVPreF3 OA specific CD4+ T cells, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

End point type	Secondary
End point timeframe:	
At 6 months and at 12 months after study intervention administration	

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[34]	0 ^[35]	0 ^[36]	0 ^[37]
Units: CD4+ T cells/million cells				
geometric mean (standard deviation)	()	()	()	()

Notes:

[34] - Data for this analysis will be updated at the time of final posting.

[35] - Data for this analysis will be updated at the time of final posting.

[36] - Data for this analysis will be updated at the time of final posting.

[37] - Data for this analysis will be updated at the time of final posting.

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[38]			
Units: CD4+ T cells/million cells				
geometric mean (standard deviation)	()			

Notes:

[38] - Data for this analysis will be updated at the time of final posting.

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers, up to one month post-intervention

End point title	Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers, up to one month post-intervention
-----------------	---

End point description:

Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Analysis was performed on Cell-Mediated immune (CMI) sub-cohort of the PPS, which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for RSVPreF3 OA specific CD8+ T cells, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	46	28	55	27
Units: CD8+ T cells/million cells				
geometric mean (standard deviation)				
Day 1	10.1 (± 1.1)	6.0 (± 0.9)	15.5 (± 1.0)	10.8 (± 1.1)
Day 31	15.2 (± 1.1)	11.9 (± 1.1)	18.1 (± 1.1)	4.8 (± 1.1)

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	25			
Units: CD8+ T cells/million cells				
geometric mean (standard deviation)				
Day 1	13.2 (± 1.0)			
Day 31	13.3 (± 1.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers, at Month 6 and Month 12 post-intervention

End point title	Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers, at Month 6 and Month 12 post-intervention
-----------------	---

End point description:

Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Analysis was performed on Cell-Mediated immune (CMI) sub-cohort of the PPS, which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for RSVPreF3 OA specific CD8+ T cells, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 months and at 12 months after study intervention administration

End point values	Adults HA-RSV Group	Adults HA-Placebo Group	Adults AIR-RSV Group	Adults AIR-Placebo Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[39]	0 ^[40]	0 ^[41]	0 ^[42]
Units: CD8+ T cells/million cells				
geometric mean (standard deviation)	()	()	()	()

Notes:

[39] - Data for this analysis will be updated at the time of final posting.

[40] - Data for this analysis will be updated at the time of final posting.

[41] - Data for this analysis will be updated at the time of final posting.

[42] - Data for this analysis will be updated at the time of final posting.

End point values	OA-RSV Group			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[43]			
Units: CD8+ T cells/million cells				
geometric mean (standard deviation)	()			

Notes:

[43] - Data for this analysis will be updated at the time of final posting.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

SAEs were reported from Day 1 (day of vaccination) until Month 6 post-dose administration. Solicited and unsolicited AEs were reported from Day 1 up to 30 days post dose administration.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	v26.0
--------------------	-------

Reporting groups

Reporting group title	Adults HA-RSV Group
-----------------------	---------------------

Reporting group description:

Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

Reporting group title	Adults HA-Placebo Group
-----------------------	-------------------------

Reporting group description:

Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

Reporting group title	OA-RSV Group
-----------------------	--------------

Reporting group description:

Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

Reporting group title	Adults AIR-Placebo Group
-----------------------	--------------------------

Reporting group description:

Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

Reporting group title	Adults AIR-RSV Group
-----------------------	----------------------

Reporting group description:

Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

Serious adverse events	Adults HA-RSV Group	Adults HA-Placebo Group	OA-RSV Group
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 383 (0.52%)	4 / 192 (2.08%)	9 / 381 (2.36%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			

subjects affected / exposed	0 / 383 (0.00%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol poisoning			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kyphosis postoperative			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Pericarditis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebellar stroke			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cerebrovascular accident			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Cold type haemolytic anaemia			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Inguinal hernia			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Non-alcoholic fatty liver			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			

subjects affected / exposed	0 / 383 (0.00%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Gouty arthritis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess oral			
subjects affected / exposed	0 / 383 (0.00%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	2 / 381 (0.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute sinusitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Obesity			
subjects affected / exposed	0 / 383 (0.00%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Adults AIR-Placebo Group	Adults AIR-RSV Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 191 (2.09%)	14 / 386 (3.63%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Femur fracture			

subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kyphosis postoperative			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Pericarditis			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebellar stroke			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			

Cold type haemolytic anaemia subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Inguinal hernia subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Non-alcoholic fatty liver subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease subjects affected / exposed	0 / 191 (0.00%)	2 / 386 (0.52%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			

Gouty arthritis			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess oral			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 191 (0.52%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 191 (0.00%)	3 / 386 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Acute sinusitis			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Obesity			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Adults HA-RSV Group	Adults HA-Placebo Group	OA-RSV Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	323 / 383 (84.33%)	76 / 192 (39.58%)	278 / 381 (72.97%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Uterine leiomyoma			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Breast cancer			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Administration site bruise			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Administration site warmth			

subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Injection site pruritus			
subjects affected / exposed	3 / 383 (0.78%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	3	0	0
Injection site pain			
subjects affected / exposed	288 / 383 (75.20%)	20 / 192 (10.42%)	233 / 381 (61.15%)
occurrences (all)	288	20	233
Injection site induration			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Injection site erythema			
subjects affected / exposed	40 / 383 (10.44%)	1 / 192 (0.52%)	42 / 381 (11.02%)
occurrences (all)	40	1	42
Injection site bruising			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	1 / 383 (0.26%)	1 / 192 (0.52%)	2 / 381 (0.52%)
occurrences (all)	1	1	2
Fatigue			
subjects affected / exposed	165 / 383 (43.08%)	34 / 192 (17.71%)	91 / 381 (23.88%)
occurrences (all)	166	34	91
Chills			
subjects affected / exposed	2 / 383 (0.52%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	2	0	0
Chest pain			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Asthenia			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	3 / 381 (0.79%)
occurrences (all)	1	0	3
Injection site swelling			
subjects affected / exposed	32 / 383 (8.36%)	2 / 192 (1.04%)	25 / 381 (6.56%)
occurrences (all)	32	2	25
Peripheral swelling			

subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	14 / 383 (3.66%) 14	2 / 192 (1.04%) 2	7 / 381 (1.84%) 7
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Dyspnoea subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	1 / 381 (0.26%) 1
Bronchospasm subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	2 / 381 (0.52%) 2
Cough subjects affected / exposed occurrences (all)	3 / 383 (0.78%) 3	0 / 192 (0.00%) 0	2 / 381 (0.52%) 2
Sinus congestion subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Rhinorrhoea subjects affected / exposed occurrences (all)	3 / 383 (0.78%) 3	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 383 (0.52%) 2	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Nasal congestion			

subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Throat irritation subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	2 / 383 (0.52%) 2	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Investigations Blood pressure increased subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Helicobacter test positive subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Injury, poisoning and procedural complications Contusion subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Immunisation reaction subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Meniscus injury subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Post-traumatic pain subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Soft tissue injury			

subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Rib fracture subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Cardiac disorders			
Angina pectoris subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Cardiac failure chronic subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Cardiac failure subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Nervous system disorders			
Carotid arteriosclerosis subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Taste disorder subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Sinus headache subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Sciatica			

subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Migraine			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Headache			
subjects affected / exposed	137 / 383 (35.77%)	34 / 192 (17.71%)	81 / 381 (21.26%)
occurrences (all)	139	35	81
Dizziness			
subjects affected / exposed	1 / 383 (0.26%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences (all)	2	1	0
Carpal tunnel syndrome			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Lymphadenopathy			
subjects affected / exposed	3 / 383 (0.78%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences (all)	3	1	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Vitreous floaters			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Ocular retrobulbar haemorrhage			

subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Diabetic retinopathy			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	1 / 383 (0.26%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences (all)	1	1	0
Abdominal pain			
subjects affected / exposed	2 / 383 (0.52%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	2	0	1
Abdominal wall haematoma			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	3 / 383 (0.78%)	1 / 192 (0.52%)	3 / 381 (0.79%)
occurrences (all)	3	1	3
Hiatus hernia			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Large intestine polyp			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1

Nausea			
subjects affected / exposed	3 / 383 (0.78%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	3	0	0
Vomiting			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	2 / 381 (0.52%)
occurrences (all)	1	0	2
Toothache			
subjects affected / exposed	1 / 383 (0.26%)	1 / 192 (0.52%)	1 / 381 (0.26%)
occurrences (all)	1	1	1
Poor dental condition			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Odynophagia			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Noninfective sialoadenitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Hepatic fibrosis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Dermatitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Actinic keratosis			

subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Eczema nummular subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Macule subjects affected / exposed occurrences (all)	1 / 383 (0.26%) 1	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Psoriasis subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Acute kidney injury subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	101 / 383 (26.37%)	12 / 192 (6.25%)	50 / 381 (13.12%)
occurrences (all)	102	12	51
Back pain			
subjects affected / exposed	4 / 383 (1.04%)	1 / 192 (0.52%)	3 / 381 (0.79%)
occurrences (all)	4	1	3
Rotator cuff syndrome			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	2 / 383 (0.52%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	2	0	0
Muscle contracture			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	148 / 383 (38.64%)	12 / 192 (6.25%)	82 / 381 (21.52%)
occurrences (all)	149	13	83
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Chronic sinusitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	2 / 381 (0.52%)
occurrences (all)	0	0	2
COVID-19			

subjects affected / exposed	2 / 383 (0.52%)	1 / 192 (0.52%)	5 / 381 (1.31%)
occurrences (all)	2	1	5
Bronchitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	2 / 381 (0.52%)
occurrences (all)	0	0	2
Oral herpes			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	1	0	0
Otitis media			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Gastrointestinal viral infection			
subjects affected / exposed	0 / 383 (0.00%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences (all)	0	1	0
Herpes simplex			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	2	0	0
Pharyngitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Labyrinthitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Laryngitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	4 / 383 (1.04%)	3 / 192 (1.56%)	5 / 381 (1.31%)
occurrences (all)	4	3	5
Influenza			
subjects affected / exposed	1 / 383 (0.26%)	0 / 192 (0.00%)	2 / 381 (0.52%)
occurrences (all)	1	0	2
Pharyngitis streptococcal			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			

subjects affected / exposed	0 / 383 (0.00%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 383 (0.00%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Suspected COVID-19			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Tooth infection			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 383 (0.52%)	0 / 192 (0.00%)	5 / 381 (1.31%)
occurrences (all)	2	0	5
Urinary tract infection			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	1 / 381 (0.26%)
occurrences (all)	0	0	1
Viral infection			
subjects affected / exposed	1 / 383 (0.26%)	2 / 192 (1.04%)	0 / 381 (0.00%)
occurrences (all)	2	2	0
Viral upper respiratory tract infection			
subjects affected / exposed	2 / 383 (0.52%)	1 / 192 (0.52%)	0 / 381 (0.00%)
occurrences (all)	2	1	0
Metabolism and nutrition disorders			
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 383 (0.00%)	0 / 192 (0.00%)	0 / 381 (0.00%)
occurrences (all)	0	0	0

Impaired fasting glucose subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	1 / 192 (0.52%) 1	0 / 381 (0.00%) 0
Vitamin B12 deficiency subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Dyslipidaemia subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Electrolyte imbalance subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Gout subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	0 / 381 (0.00%) 0
Hyperphagia subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 383 (0.00%) 0	0 / 192 (0.00%) 0	1 / 381 (0.26%) 1

Non-serious adverse events	Adults AIR-Placebo Group	Adults AIR-RSV Group	
Total subjects affected by non-serious adverse events subjects affected / exposed	72 / 191 (37.70%)	317 / 386 (82.12%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	0 / 386 (0.00%) 0	
Breast cancer subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	1 / 386 (0.26%) 1	
Vascular disorders			

Hypertension subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	1 / 386 (0.26%) 1	
General disorders and administration site conditions			
Administration site bruise subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	1 / 386 (0.26%) 1	
Administration site warmth subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	1 / 386 (0.26%) 1	
Injection site pruritus subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	3 / 386 (0.78%) 3	
Injection site pain subjects affected / exposed occurrences (all)	26 / 191 (13.61%) 26	285 / 386 (73.83%) 285	
Injection site induration subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	0 / 386 (0.00%) 0	
Injection site erythema subjects affected / exposed occurrences (all)	1 / 191 (0.52%) 1	55 / 386 (14.25%) 55	
Injection site bruising subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	0 / 386 (0.00%) 0	
Influenza like illness subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	0 / 386 (0.00%) 0	
Fatigue subjects affected / exposed occurrences (all)	36 / 191 (18.85%) 36	135 / 386 (34.97%) 135	
Chills subjects affected / exposed occurrences (all)	0 / 191 (0.00%) 0	1 / 386 (0.26%) 1	
Chest pain			

subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Asthenia			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Injection site swelling			
subjects affected / exposed	1 / 191 (0.52%)	43 / 386 (11.14%)	
occurrences (all)	1	43	
Peripheral swelling			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Pyrexia			
subjects affected / exposed	3 / 191 (1.57%)	11 / 386 (2.85%)	
occurrences (all)	3	11	
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 191 (0.52%)	2 / 386 (0.52%)	
occurrences (all)	1	2	
Dyspnoea			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Bronchospasm			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Cough			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	
Sinus congestion			

subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Rhinorrhoea			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Oropharyngeal pain			
subjects affected / exposed	2 / 191 (1.05%)	2 / 386 (0.52%)	
occurrences (all)	2	2	
Nasal congestion			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Epistaxis			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Throat irritation			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Insomnia			
subjects affected / exposed	1 / 191 (0.52%)	1 / 386 (0.26%)	
occurrences (all)	1	1	
Investigations			
Blood pressure increased			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Helicobacter test positive			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Immunisation reaction			

subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Meniscus injury			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Post-traumatic pain			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Soft tissue injury			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Rib fracture			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Atrial fibrillation			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Supraventricular tachycardia			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	
Palpitations			
subjects affected / exposed	0 / 191 (0.00%)	2 / 386 (0.52%)	
occurrences (all)	0	2	
Cardiac failure chronic			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Cardiac failure			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Carotid arteriosclerosis			

subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Taste disorder			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Sinus headache			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	
Sciatica			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	
Post herpetic neuralgia			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Migraine			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Headache			
subjects affected / exposed	32 / 191 (16.75%)	106 / 386 (27.46%)	
occurrences (all)	33	106	
Dizziness			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Carpal tunnel syndrome			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Lymphadenopathy			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Eye disorders			
Cataract			

subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Vitreous floaters			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Vision blurred			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Ocular retrobulbar haemorrhage			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Diabetic retinopathy			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Abdominal pain			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Abdominal wall haematoma			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Haemorrhoids			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Dyspepsia			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Dry mouth			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Diarrhoea			
subjects affected / exposed	2 / 191 (1.05%)	4 / 386 (1.04%)	
occurrences (all)	2	4	

Hiatus hernia			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Inguinal hernia			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Large intestine polyp			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	0 / 191 (0.00%)	3 / 386 (0.78%)	
occurrences (all)	0	3	
Vomiting			
subjects affected / exposed	0 / 191 (0.00%)	2 / 386 (0.52%)	
occurrences (all)	0	2	
Toothache			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Poor dental condition			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	
Odynophagia			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Noninfective sialoadenitis			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Hepatic fibrosis			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			

Dermatitis atopic		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Dermatitis allergic		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Dermatitis		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Actinic keratosis		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Dry skin		
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)
occurrences (all)	1	0
Eczema nummular		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Erythema		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Macule		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Urticaria		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Skin lesion		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Rash		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Psoriasis		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0

Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Acute kidney injury			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	19 / 191 (9.95%)	80 / 386 (20.73%)	
occurrences (all)	19	81	
Back pain			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Rotator cuff syndrome			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Muscle spasms			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Muscle contracture			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Joint swelling			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Myalgia			
subjects affected / exposed	26 / 191 (13.61%)	122 / 386 (31.61%)	
occurrences (all)	26	122	
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)	
occurrences (all)	1	0	

Ear infection		
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)
occurrences (all)	1	0
Chronic sinusitis		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
COVID-19		
subjects affected / exposed	1 / 191 (0.52%)	2 / 386 (0.52%)
occurrences (all)	1	2
Bronchitis		
subjects affected / exposed	1 / 191 (0.52%)	1 / 386 (0.26%)
occurrences (all)	1	1
Oral herpes		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Otitis media		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Gastrointestinal viral infection		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Herpes simplex		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Pharyngitis		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Labyrinthitis		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Laryngitis		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Nasopharyngitis		
subjects affected / exposed	0 / 191 (0.00%)	6 / 386 (1.55%)
occurrences (all)	0	6

Influenza		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Pharyngitis streptococcal		
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)
occurrences (all)	0	1
Respiratory tract infection		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Respiratory tract infection viral		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Rhinitis		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Sinusitis		
subjects affected / exposed	0 / 191 (0.00%)	3 / 386 (0.78%)
occurrences (all)	0	3
Suspected COVID-19		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Tooth infection		
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)
occurrences (all)	1	0
Upper respiratory tract infection		
subjects affected / exposed	2 / 191 (1.05%)	3 / 386 (0.78%)
occurrences (all)	2	3
Urinary tract infection		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0
Viral infection		
subjects affected / exposed	1 / 191 (0.52%)	0 / 386 (0.00%)
occurrences (all)	1	0
Viral upper respiratory tract infection		
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)
occurrences (all)	0	0

Metabolism and nutrition disorders			
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 191 (0.00%)	2 / 386 (0.52%)	
occurrences (all)	0	2	
Impaired fasting glucose			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Vitamin B12 deficiency			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Dyslipidaemia			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Electrolyte imbalance			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Gout			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Hyperglycaemia			
subjects affected / exposed	0 / 191 (0.00%)	1 / 386 (0.26%)	
occurrences (all)	0	1	
Hyperphagia			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	
Hypokalaemia			
subjects affected / exposed	0 / 191 (0.00%)	0 / 386 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 May 2023	The purpose of this amendment was to record events of atrial fibrillation (AF) as Adverse Events of Special Interest (AESIs).

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported